文献速递临床试验与 GCP

微脉冲经巩膜睫状体光凝与慢速凝固治疗难治性青光眼:随机临床试验研究方案

Micropulse transscleral cyclophotocoagulation versus slow coagulation in refractory glaucoma: study protocol of a randomized clinical trial.
PubMed 文献 · Trials · 2025-06-04

该文描述了一项单中心、双盲、平行双组随机临床试验方案,纳入矫正视力≤20/60、眼压>21 mmHg且年龄≥18岁的难治性青光眼患眼,随机接受微脉冲经巩膜睫状体光凝(MP-TSCPC)或慢速凝固(SC-TSCPC),随访12个月,比较两种技术的有效性与安全性。

要点

  • 方案纳入难治性青光眼患眼,矫正视力≤20/60、眼压>21 mmHg、年龄≥18岁。
  • 随机分组至MP-TSCPC或SC-TSCPC,随访至术后12个月。
  • 完全成功定义为眼压6–20 mmHg且较基线下降至少30%,不使用降眼压药物。

核心结论

  • 作者认为这是首个比较MP-TSCPC与SC-TSCPC技术的随机临床试验。

研究设计与样本

  • 平行双组、单中心、双盲随机临床试验方案,纳入难治性青光眼患眼。

主要发现

  • 多数已发表的经巩膜睫状体光凝研究为回顾性病例系列,治疗方案各异。
  • 已发表研究多将两种新技术仅与传统技术比较。

关键数值与推荐

  • 完全成功:眼压6–20 mmHg且较基线下降至少30%,不使用降眼压药物。
  • 部分成功:采用相同参数但允许使用降眼压药物。
  • 随访时间点为术后1天、7天、30天、3个月、6个月和12个月。
  • 矫正视力≤20/60、眼压>21 mmHg、年龄≥18岁者纳入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional continuous diode laser transscleral cyclophotocoagulation (TCW-TSCPC) has been used for decades to reduce intraocular pressure (IOP) by decreasing aqueous humor (AH) production in patients with glaucoma. Micropulse cyclophotocoagulation (MP-TSCPC) and slow coagulation (SC-TSCPC) are the newest transscleral cyclophotocoagulation (TSCPC) techniques that result in lower inflammation and complication rates compared to the traditional technique. Most publications on TSCPC are case series with a retrospective design with different treatment protocols. The objective of this manuscript is to describe the protocol of a randomized clinical trial (RCT) designed to compare the efficacy and safety of MP-TSCPC and SC-TSCPC in patients with refractory glaucoma followed for 12 months. METHODS: This is a parallel, double-arm single-center, double-masked, RCT that will include eyes with refractory glaucoma. Patients with corrected visual acuity (BCVA) ≤ 20/60, IOP > 21 mmHg, and age ≥ 18 years will be randomized to cyclophotocoagulation using the SC-TSCPC or MP-TSCPC techniques. Follow-up visits will be 1 day, 7 days, 30 days, 3, 6, and 12 months after the procedure. Complete success will be defined as an IOP between 6 and 20 mmHg and a minimum of 30% IOP reduction from baseline, without hypotensive medications. Qualified success will be defined by the same parameters but allowing the use of medication. All follow-up examinations will include determination of BCVA, IOP measurement, slit lamp biomicroscopy, fundoscopy, and macular optical coherence tomography (OCT). The number of hypotensive medications and the occurrence of complications will also be documented. DISCUSSION: Our study was designed to compare the efficacy and safety of the two most used TSCPC techniques. Most published studies are retrospective and compare the two new techniques only with the traditional technique. This is, to our knowledge, the first RCT comparing MP-TSCPC and SC-TSCPC techniques. TRIAL REGISTRATION: Retrospectively registered at the Registro Brasileiro de Ensaios Clínicos (ReBEC) platform RBR-5pckbhj on December 15, 2023. The study was approved by the Ethics Committee of the University of Campinas, Brazil.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. de Lima Neto CR, de Cabral Vasconcellos JP, Silva SGNE, et al. Micropulse transscleral cyclophotocoagulation versus slow coagulation in refractory glaucoma: study protocol of a randomized clinical trial. Trials. 2025. PMID: 40468395. doi:10.1186/s13063-025-08907-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。